Fulfilling the dream: tolerogenic dendritic cells to treat multiple sclerosis
- PMID: 22488360
- DOI: 10.1002/eji.201242402
Fulfilling the dream: tolerogenic dendritic cells to treat multiple sclerosis
Abstract
Autoimmune diseases including multiple sclerosis (MS) are the result of an imbalanced immune tolerance network. Dendritic cells (DCs) are key players in both initiating immunity (immunogenic DCs) and regulating immune responses (tolerogenic DCs = tolDCs) and are potential targets for the treatment of MS. While the immunogenic potential of DCs in fighting infection and cancer has been well established, approaches that exploit their tolerogenic features to promote transplantation tolerance and autoimmunity have emerged only more recently. TolDCs usually maintain antigen-specific T-cell tolerance either directly by inducing anergy, apoptosis, or phenotype skewing or indirectly by induction of regulatory T (Treg) cells. The use of ex vivo-generated tolDCs is an experimental approach to achieve tolerance towards myelin-antigen-specific CD4(+) T cells. In the article by Raϊch-Regué and colleagues (Eur. J. Immunol. 2011. 42:772-783) in this issue of the European Journal of Immunology, advances in human tolDC preparation and promise for autologous therapy are described. These findings raise hopes of achieving the "ideal" of a highly-specific, causally-oriented immune intervention for central nervous system (CNS) autoimmunity in MS. However, recent experience with antigen-specific immune interventions in MS and some general caveats associated with cell-based-therapies highlight the challenges for clinical translation of the "immunologist's dream" of treating autoimmunity as discussed in this Commentary.
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Comment on
-
Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients.Eur J Immunol. 2012 Mar;42(3):771-82. doi: 10.1002/eji.201141835. Eur J Immunol. 2012. PMID: 22488365 Clinical Trial.
Similar articles
-
Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients.Eur J Immunol. 2012 Mar;42(3):771-82. doi: 10.1002/eji.201141835. Eur J Immunol. 2012. PMID: 22488365 Clinical Trial.
-
Tolerogenic Dendritic Cells Generated with Tofacitinib Ameliorate Experimental Autoimmune Encephalomyelitis through Modulation of Th17/Treg Balance.J Immunol Res. 2016;2016:5021537. doi: 10.1155/2016/5021537. Epub 2016 Dec 13. J Immunol Res. 2016. PMID: 28070525 Free PMC article.
-
Tolerogenic dendritic cell vaccines to treat autoimmune diseases: can the unattainable dream turn into reality?Autoimmun Rev. 2014 Feb;13(2):138-50. doi: 10.1016/j.autrev.2013.09.008. Epub 2013 Oct 9. Autoimmun Rev. 2014. PMID: 24120737 Review.
-
Immune checkpoints and the regulation of tolerogenicity in dendritic cells: Implications for autoimmunity and immunotherapy.Autoimmun Rev. 2019 Apr;18(4):359-368. doi: 10.1016/j.autrev.2019.02.006. Epub 2019 Feb 8. Autoimmun Rev. 2019. PMID: 30738957 Review.
-
Role of dendritic cells in the initiation, progress and modulation of systemic autoimmune diseases.Autoimmun Rev. 2015 Feb;14(2):127-39. doi: 10.1016/j.autrev.2014.10.010. Epub 2014 Oct 14. Autoimmun Rev. 2015. PMID: 25449681 Review.
Cited by
-
Targeting dendritic cell function during systemic autoimmunity to restore tolerance.Int J Mol Sci. 2014 Sep 16;15(9):16381-417. doi: 10.3390/ijms150916381. Int J Mol Sci. 2014. PMID: 25229821 Free PMC article. Review.
-
Dendritic cells, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase and pulsed with a myelin antigen, provide myelin-specific suppression of ongoing experimental allergic encephalomyelitis.FASEB J. 2017 Jul;31(7):2996-3006. doi: 10.1096/fj.201601243R. Epub 2017 Mar 31. FASEB J. 2017. PMID: 28363955 Free PMC article.
-
Tolerogenic dendritic cells induced by BD750 ameliorate proinflammatory T cell responses and experimental autoimmune encephalitis in mice.Mol Med. 2017 Oct;23:204-214. doi: 10.2119/molmed.2016.00110. Epub 2017 Sep 27. Mol Med. 2017. PMID: 28960227 Free PMC article.
-
Human dendritic cell subsets in vaccination.Curr Opin Immunol. 2013 Jun;25(3):396-402. doi: 10.1016/j.coi.2013.05.001. Epub 2013 May 30. Curr Opin Immunol. 2013. PMID: 23725656 Free PMC article. Review.
-
Targeting human dendritic cells in situ to improve vaccines.Immunol Lett. 2014 Nov;162(1 Pt A):59-67. doi: 10.1016/j.imlet.2014.07.004. Epub 2014 Jul 27. Immunol Lett. 2014. PMID: 25072116 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
